The MarketWatch News Department was not involved in the creation of this content. -- Study data also showed prolonged progression-free survival with 177Lu-edotreotide compared to everolimus across ...

Phase 1b trial shows 40% response rate for onvansertib plus paclitaxel in metastatic triple-negative breast cancer, with manageable toxicity. Cardiff Oncology, Inc. announced promising results from a ...

Xilio Therapeutics reports 26% response rate for vilastobart and atezolizumab in metastatic MSS CRC patients, with favorable safety profile. Xilio Therapeutics has reported promising results from its ...

75% Objective Response Rate as 12 out of 16 advanced melanoma patients had objective clinical responses, with 11 of the 12 responders continuing to respond at 24 months follow-up Immune activation ...

Danish vaccine developer Evaxion has released long-term data for its lead personalized cancer vaccine, with the shot scoring a 75% objective response rate (ORR) in patients with advanced melanoma ...